Web Presence LLC, DBA NetReputation has donated $7,500 to help seventeen-year-old Zach Hirsch build homes for Haitian families affected by devastating earthquake.

SARASOTA, FL / ACCESSWIRE / December 9, 2019 / The ramifications of the earthquake that occurred in January 2010 in the country of Haiti continue to be felt to this day. Millions of survivors have been displaced, broken apart, and still have no place to call home. The Sarasota based reputation management company Web Presence LLC has recently made a sizable donation to a deserving cause, headed by one thoughtful teen.

When high-schooler Zachary Hirsch was able to visit Haiti as part of a mission with the Be Like Brit program, he was moved to action. "My life changed forever in 2017 when we were able to build a home for a family who never had one…I got to spend time with wonderful people who have almost nothing and appreciate everything," he explains on his fundraiser page. He goes on to vow: "When I returned to my home where I have so much, I promised myself I would continue to help those who don't in Haiti."

Be Like Brit Foundation

Lynn University student Britney Gengel was on a service trip to Haiti in 2010 when the earthquake struck. Tragically, she perished alongside hundreds of thousands of others. Her spirit lives on through the Be Like Brit Foundation: this foundation serves the children of Haiti in the form of an orphanage where the goal is a shelter, education, and love for every child.

The Be Like Brit Foundation offers a program that allows American teenagers the chance to travel to Haiti in order to participate in community outreach, help those in need, and broaden their own global understanding by witnessing firsthand the harsh poverty a natural disaster left unattended can bestow upon a community.

"We are thrilled to have the opportunity to help Zach and the Be Like Brit foundation rebuild Haiti after the 2010 earthquake," Adam Petrilli, CEO of NetReputation.com tells us.

Taking Action

Despite promising himself he would do everything in his power to continue helping the people of Haiti after his initial trip with the Be Like Brit Foundation, unfortunately, Zachary Hirsch was unable to return to Haiti for a second year. In 2018, it was deemed a security risk for Zach and his classmates to return to Haiti-so, Zach took matters into his own hands, and raised enough money to build a new home for a family in need.

This year, Zach aimed to raise the bar. His new goal was to raise enough money to build five homes for families in Haiti, and thanks to a generous donation from Web Presence LLC, he's been able to reach this goal.

About NetReputation

NetReputation is no stranger to helping spread positivity-a large part of their business model is based around promoting positive information for their clients. NetReputation is a reputation management company concerned with helping people and businesses portray the best possible versions of themselves on the internet. They achieve this through a combination of promoting positive content and suppressing unwanted and incorrect information.

NetReputation was founded in 2014 by CEO Adam Petrilli. This year it has been named the #208 Most Successful Company in America, #20 in Florida Companies, and #18 in Advertising and Marketing by Inc., a leading source of business information.

CONTACT:

Caroline Hunter
Web Presence, LLC
+1 7865519491

SOURCE: Web Presence, LLC

ReleaseID: 569539

TORONTO, ON / ACCESSWIRE / December 9, 2019 / PJX Resources Inc. ("PJX" or "the Company") is pleased to announce that the New Massive Sulphide ("NMS") zone recently intersected in hole VA19-48 corresponds with a strong conductive Electromagnetic (EM) anomaly identified by recent down hole geophysics on the Vine Property. The NMS zone is very conductive and occurs at the edge of the newly identified strongly conductive EM anomaly which supports the NMS zone may be part of a larger body.

"This is very encouraging news," states John Keating. "The NMS zone we recently intersected appears to be the same massive sulphide horizon that was intersected over 700 metres to the south by a hole drilled in the 1990's. No holes have been drilled to test the NMS horizon between these holes or to the north and west. Down hole and surface geophysics suggest we intersected the edge of the NMS zone that has potential to be laterally extensive, similar to what occurs at the Sullivan deposit. Final compilation of the results is underway with drilling planned to start in January. In addition, recent drilling on the Gold Shear Property was just completed and results are pending."

Down hole geophysics on drill hole VA19-48 also identified a moderate EM conductive anomaly that appears to correspond with the Sullivan Horizon, which is the geological horizon hosting the Sullivan massive sulphide deposit located 35 kilometres north of the Vine Property. This EM target occurs off the hole and has not yet been tested by drilling.

Highlights

PJX drill hole VA19-48 recently intersected a new massive sulphide ("NMS") zone, from 777.1 – 782.6 metres. The zone has 4 layers that consist largely of conductive massive iron-sulphides with anomalous zinc, copper, lead, and silver.
Recent down hole EM geophysics, by Quantec Geoscience, has delineated two conductor anomalies, located at depths of about 340 metres (m) and 780m in drill hole VA19-48.
EM anomaly at 340m depth appears to correspond with the Sullivan time horizon that hosts the Sullivan deposit. This is an off-hole anomaly as it is located away from the hole and was not intersected by the drill hole. The anomaly is located to the south and west of hole VA19-48 and has moderate conductivity thickness of 100 siemens.
EM anomaly at 780m depth is stronger and corresponds with the New Massive Sulphide (NMS) horizon containing 4 layers of massive sulphide mineralization. Hole VA19-48 intersected the northern edge of the EM anomaly that extends to the south and west of the hole. The anomaly is very conductive with a conductivity thickness greater than 2,000 siemens.
Historical hole KV90-41, drilled by Kokanee Exploration in 1990, intersected a 3.4 metre thick massive sulphide zone grading 5.65 lead, 2.7% zinc and 1.2 ounces/ton silver.

The Kokanee hole is located south of PJX's hole VA19-48. The holes are 700 metres apart and appear to have intersected the same mineralized NMS horizon.
No holes have been drilled to test the NMS horizon between these two holes or on strike and down dip to the north and west.
Magnetotelluric ("MT") Geophysics has identified a large MT target.
The NMS zone occurs at the top of the large MT target.
According to Quantec Geoscience data, the large MT target has an 800-metre strike length and can be traced down dip for over 2,000 metres.
Recent thin section analysis of core samples by Vancouver Petrographics Ltd. has identified granofels alteration, beneath the NMS horizon, that is considered to occur in areas with high heat flow, such as venting environments on the ocean floor; a similar alteration occurs beneath the Sullivan Deposit.

The foregoing geological disclosure has been reviewed and approved by John Keating P.Geo. (qualified persons for the purpose of National Instrument 43-101 Standards of Disclosure for Mineral Projects). Mr. Keating is the President, Chief Executive Officer and a Director of PJX.

Private Placement

The Company is also pleased to announce that, subject to TSX Venture Exchange approval, it has completed a non-brokered private placement initially announced by the Company on October 15, 2019 (the "Offering") for total proceeds of $1,409,200.

The Company issued a cumulative total of 5,277,158 Flow-through Units ("Flow-Through Units") and Flow-through Shares for gross proceeds of $830,450 and 3,858,333 Units for gross proceeds of $578,750.

Each Flow-through Unit consists of one common share to be issued as a "flow-through share" within the meaning of the Income Tax Act (Canada) (the "Flow-through Shares") and one common share purchase warrant. Each Flow-through share consists of one common share to be issued as a "flow-through share" within the meaning of the Income Tax Act (Canada). Each Unit consists of one common share and one common share purchase warrant. Each warrant, whether acquired as part of a Flow-through Unit or Unit, entitles the holder to purchase one common share at an exercise price of $0.25 for 36 months following completion of the Offering.

In connection with closing the Offering, the Company may pay, in accordance with the policies and subject to regulatory approval, aggregate cash finder's fees of $99,228 and issue certain Finders 649,733 non-transferable Finder's Warrants. Each of the Finder's Warrants entitles the Finder to purchase one common share of the Company at a price of $0.25 per Finder Share for 36 months following completion of the Offering.

About PJX Resources Inc.

PJX is a mineral exploration company focused on building shareholder value and community opportunity through the exploration and development of mineral resources with a focus on gold and base metals. PJX's properties are located in the historical mining area of Cranbrook and Kimberley, British Columbia. Please refer to our web site http://www.pjxresources.com for additional information.

FOR FURTHER INFORMATION PLEASE CONTACT:

Linda Brennan, Chief Financial Officer
(416) 799-9205
info@pjxresources.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This News Release contains forward-looking statements. Forward looking statements are statements which relate to future events. Forward-looking statements include, but are not limited to, statements with respect to exploration results, the success of exploration activities, mine development prospects, completion of economic assessments, and future gold production. In some cases, you can identify forward-looking statements by terminology such as "may", "appears to", "should", "expects", "plans", "anticipates", believes", "estimates", "predicts", "potential", or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking-statements.

Although PJX has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

SOURCE: PJX Resources Inc.

ReleaseID: 569509

DUBAI, UNITED ARAB EMIRATES / ACCESSWIRE / December 9, 2019 / Blockchain-based online community management platform GLBrain that aims to make communication, content sharing, and networking transparent and faster, has now amassed more force to reach its full potential. This is because it now has Dr. Evan Luthra, an acclaimed blockchain investor, and mentor, at the helm of its product cycle and upcoming Token Sale.

GLBrain won £50,000 from Dr. Evan Luthra in London this October

CEO of GLBrain, Dr. Wolfgang Pinegger said that he is excited to have Evan on board. He said that he is positive that Dr. Luthra's rich experience in building and scaling technology companies from the ground up will go a long way in giving GLBrain the direction it needs to achieve its goals.

Dr. Evan Luthra is a young entrepreneur but has the business acumen of a seasoned innovator and investor. He embarked on his entrepreneurial venture when he was just 13 years old. However, within a short period, he was already building ingenious mobile apps and investing in technologies that he knew would revolutionize industries.

In a matter of a few years alone, Evan has gained mastery over blockchain technology and helped bring numerous products in the industry to completion. Today, he is sharing his wisdom and experience with forward-thinking entrepreneurs and blockchain pioneers around the world to pave the path for a better future.

"Having received both financial backing and business direction from Evan, I feel like we have the perfect man on our team", Pinegger said. "We have already built a platform that's robust and truly one-of-a-kind. Now that Evan has shared his vision for the project, we are confident that we will introduce the world to a revolutionary online community management platform."

Apart from Dr. Evan Luthra, who is alone a huge addition to the GLBrain team, "The Bitcoin Man" Herbert R. Sim has also decided to be a part of the project as a key advisor. He is a well-known entrepreneur, writer, philanthropist, and investor and also the founder of Crypto Chain University (CCU). His experience in the blockchain industry will be of huge help for the GLBrain team.

About GLBrain

GLBrain is a new-age online community management, social network, and marketing platform that uses the features of blockchain technology and distributed ledger technology to deliver solutions for our future. It offers its users a unique range of communication, content-sharing, and community management and online marketing functions while at the same time giving them absolute privacy and ownership over their data

Media Contact

Name: Wolfgang Pinegger
Email ID: wolfgang@glbrain.com

SOURCE: GLBrain

ReleaseID: 569537

VANCOUVER, BC, ACCESSWIRE / December 9, 2019 / Chemesis International Inc. (CSE:CSI) (OTCQB:CADMF) (FRA:CWAA) (the "Company" or "Chemesis"), announces, further to its news release dated November 1, 2019, that certain of the cannabis licenses ("Licenses") held by its subsidiary, Natural Ventures PR, LLC ("Natural Ventures"), remain subject to the administrative review ("Review") being undertaken by the Puerto Rico Department of Health, and that the Company has now taken the step of instructing its Puerto Rico legal team to apply to the Puerto Rico Superior Court, San Juan, for an order establishing that the Puerto Rico Department of Health's actions in regard to the Review are not consistent with the legal and regulatory framework applicable to the Licenses ("Court Application"). The Company will provide further updates as appropriate.

The Company notes that at the current time the Licenses effectively remain in abeyance, as Natural Ventures is not permitted to carry out any licensed activities under the Licenses, though it is permitted to carry out certain activities for the purposes of preserving and maintaining inventory.

On Behalf of The Board of Directors
Edgar Montero
CEO and Director

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico and Colombia.

The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets and is committed to differentiate itself by deploying resources in markets with major opportunities. The Company operates a portfolio of brands that cater to a wide community of cannabis consumers, with focus on quality and consistency.

Chemesis has facilities in both Puerto Rico and California. The Company is positioned to win additional licenses in highly competitive merit-based US states and will expand its footprint to ensure it maintains a first mover advantage.

Investor Relations:

ir@chemesis.com
1 (604) 398-3378

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business, its product offerings and plans for sales and marketing, including with respect to the Company's expectations regarding its supply and distribution arrangements, ability to realize benefits from its recent contractual arrangements, its plans to continue to develop dispensaries in Puerto Rico, and its ability to obtain licenses in additional jurisdictions. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected, including, but not limited to, in relation to executing on and maintaining its supply and distribution arrangements and recent contractual arrangements, in relation to developing dispensaries in Puerto Rico, and its ability to obtain licenses in additional jurisdictions. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

SOURCE: Chemesis International Inc.

ReleaseID: 569517

LOS ANGELES, CA / ACCESSWIRE / December 9, 2019 / Siyata Mobile Inc. (TSX-V:SIM)(OTCQX: SYATF), a developer and provider of cellular communications solutions for enterprise workers and first responders, today announced that it will be presenting at the 12th annual LD Micro Main Event on Wednesday, December 11 at 9:40 AM PST / 12:40 PM EST and meeting with institutions and high net worth investors during the two day conference December 10th and 11th.

Siyata Mobile's 4G/LTE Uniden UV350, dedicated in-vehicle smartphone is now available through the largest carriers in the United States and Canada including AT&T, FirsNet, Bell Mobility and Rogers Wireless. Through these carriers and additional distribution channels, the Company is targeting ~20M commercial fleet and first responder vehicles in North America, with no known direct competition. The UV350 reduces costs, while improving safety and functionality over a nationwide 4G cellular network of its customers choice.

Marc Seelenfreund, CEO, adds, "Siyata is now a very relevant story for U.S. investors as we are working with the leading cellular carriers in the United States. We look forward to being a part of the LD Micro Main Event and sharing how Siyata is well positioned to become a leading global vendor in the Push-to-Talk over Cellular evolution."

"This year's Main Event is our largest event to date, with 275 companies set to present and meet with investors" stated Chris Lahiji, President of LD Micro. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever-growing community. Investor interest in our events has also never been stronger, and that goes for our commitment to philanthropy as well."

The LD Micro Main Event will take place on December 10th-12th in Los Angeles, at the Luxe Sunset Bel Air Hotel, which will feature 275 companies, and will be attended by over 1,400 individuals.

View Siyata Mobile's profile here: http://www.ldmicro.com/profile/SIM.V

Profiles powered by LD Micro – News Compliments of Accesswire

About Siyata

A TSX Venture Top 50 Company, Siyata Mobile Inc. is a leading global developer and provider of cellular communications systems for enterprise customers, specializing in connected vehicle products for professional fleets, marketed under the Uniden® Cellular brand. Incorporating voice, push-to-talk over cellular, data, and fleet management solutions into a single device, the company aims to become the connected vehicle communications device of choice for commercial vehicles and fleets around the world.

Siyata also offers rugged phones for industrial users and signal boosters for homes, buildings, and fleets with poor cell coverage. Siyata's customers include cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia, and the Middle East.

Visit www.siyatamobile.com and http://www.unidencellular.com/ to learn more.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Arlen Hansen
Phone: 604 684 6730
Address: 100 – 736 Granville St, Vancouver, B.C., Canada
Email: arlen@kincommunications.com

SOURCE: Siyata Mobile Inc. via LD Micro

ReleaseID: 569507

LOS ANGELES, CA / ACCESSWIRE / December 9, 2019 / Abacus Health Products, Inc. (CSE:ABCS)(OTCQX:ABAHF) ("Abacus" or the "Company") today announced that it will be presenting at the 12th Annual LD Micro Main Event being held on December 10-12, 2019 at the Luxe Sunset Bel Air Hotel in Bel Air, California.

Jonathan Conforti, Vice President of Corporate Development, is scheduled to present on Wednesday December 11th at 11:00am PST and available for one-on-one meetings during the conference.

Abacus' leading consumer brand, CBDMEDIC, includes a line of topical pain relief and skincare products. Abacus' leadership in the CBD market is underscored by its announcement that it has received purchase orders from approximately 7,000 retail locations representing 20 chains including the 3 largest national retail pharmacy chains. The Company recently announced growing distribution as well as a partnership with 3-time football world champion Rob Gronkowski and a branding agreement with Gillette Stadium and Patriot Place.

To schedule a one-on-one meeting with Abacus Health Products, you may submit your request online via the link provided upon registration or email your request to wade@ldmicro.com. To register for the conference, contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events.

"This year's Main Event is our largest event to date, with 275 companies set to present and meet with investors" stated Chris Lahiji, President of LD Micro. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever-growing community. Investor interest in our events has also never been stronger, and that goes for our commitment to philanthropy as well."

The LD Micro Main Event will take place on December 10th-12th in Los Angeles It is one of the nation's largest independent conferences for micro-cap companies which will feature 275 companies, and will be attended by over 1,400 individuals.

View Abacus Health Product's profile here http://www.ldmicro.com/profile/ABAHF.

Profiles powered by LD Micro – News Compliments of Accesswire.

About Abacus Health Products, Inc.

Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) topical medications with active pharmaceutical ingredients. Abacus' products contain organic and natural ingredients, including hemp extract or oil containing CBD from Cannabis Sativa L. plant. Abacus' products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending formulations to provide safe and effective relief. Abacus currently offers two lines of products: (i) CBD CLINIC™, marketed to the professional practitioner market, and (ii) CBDMEDIC™, marketed to the consumer market. Abacus' products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.

To learn more about Abacus, visit www.abacushp.com

For further information: please contact Hank Hague, CFO, of the Company, at 416-848-1457 or investorrelations@abacushp.com Or Bill Mitoulas, Investor Relations, at bill@abacushp.com or 416.479.9547.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

SOURCE: Abacus Health Products via LD Micro

ReleaseID: 569494

Named 2020 FreightTech 25 and FreightTech 100 company

Ranked 63 on Idaho Private 100 fastest growing companies

Named 'Top Place for Women to Work for In Transportation' by the Women In Trucking Association (WIT)

BOISE, ID / ACCESSWIRE / December 9, 2019 / Truckstop.com, the largest neutral freight matching marketplace in North America, has been named one of the freight industry's most innovative companies, ranking 11th on the FreightWaves' FreightTech 25. Truckstop.com was also named to the FreightTech 100 in October and was the second-most nominated company at this year's awards. Sixty judges ranked the companies on the FreightTech 100 list to determine the top 25 leading innovators. FreightWaves is a digital resource for data, news and commentary about the North American freight market.

"Last year when we decided to roll out an awards recognition, we wanted to do it differently. A lot of awards in the industry are pay to play, and they end up meaning nothing," said Craig Fuller, CEO, FrieghtWaves. "We decided to create a freight tech award that has actual meaning."

"Inclusion in the FreightTech 25 is a testament to the customers and partners that keep us focused on what matters most," said Paris Cole, CEO, Truckstop.com. "Our goal has always been to help carriers and freight brokers find a better way to do business, and our success is directly connected with how well we listen and implement their feedback."

By focusing on customer needs and developing tools to make their lives easier, Truckstop.com survived and grew during two of the largest economic disasters of the 21st century-the Dot-com bubble and the recession of 2008-and positioned itself for continued growth and success. Since 2016, the company has announced two private equity investments which have helped expand its executive leadership team, add tens of thousands of customers, create hundreds of new jobs, complete multiple acquisitions, and invest heavily in product development and infrastructure build-out. The investment from ICONIQ Capital in April of this year, was one of the largest in Idaho history, and represents a significant investment in technology innovation in the State.

In addition to appearing on the FreightTech 25 and 100 lists, Truckstop.com was named to the Idaho Private 100, a list of the State's fastest-growing private companies. The Idaho Private 100 have been celebrating economic growth and development in the state for more than 20 years. Selected companies are privately owned and headquartered in Idaho. Participation is voluntary and rankings are based on company revenues from the previous fiscal year. This was the first year Truckstop.com participated in the list.

"We are proud to celebrate the businesses that make Idaho one of the top states in the country to live and work," said Rusty Dodge, Idaho Statesman Publisher and Regional VP, Northwest Sales. "Idaho's business community is an inspiring destination for talent and investment."

Truckstop.com was also recognized, for the second year in a row, in Redefining the Road magazine, the official magazine of the Women In Trucking Association (WIT), as a recipient of the 2019 "Top Companies for Women to Work For in Transportation." Companies on the list are distinguished by corporate cultures that foster gender diversity; competitive compensation and benefits; flexible hours and work requirements; professional development opportunities; and career advancement opportunities.

About Truckstop.com

For nearly 25 years, Truckstop.com has been a trusted partner for carriers and brokers in the spot market, giving them tools to be successful and efficient through the entire freight lifecycle. As the internet's largest neutral freight marketplace, Truckstop.com provides the scale of quality loads and trucks to give customers the freedom to build lasting relationships and grow their business. Whether on the road or in the office, Truckstop.com is the single source for products and solutions for the entire freight lifecycle. To learn how Truckstop.com is helping move our industry forward, visit: truckstop.com/long-haul.

CONTACT:

Truckstop.com
Matt Stubbs
Sr. Manager Public Relations & Communications
mattstubbs@truckstop.com
208-674-6031

SOURCE: Truckstop.com

ReleaseID: 569397

CORONA, CA / ACCESSWIRE / December 9, 2019 / ADOMANI, Inc. (OTCQB:ADOM), a provider of advanced zero-emission vehicle drivetrain solutions and purpose-built electric vehicles, today announced it recently received an order to repower an existing Type D diesel-powered transport bus to zero-emission electric operation.

The Fleet Management division (Fleet) of the County of Santa Clara Facilities and Fleet Department, provides vehicles to County agencies and departments to serve the transportation needs of employees and provides maintenance and repair for approximately 1,800 County vehicles. Fleet also offers 30 on-site electric vehicle charging stations, with another 79 in development, and 130 planned for future expansion. These charging stations provide a vital component for transitioning the County infrastructure to zero-emission transportation. Currently, Fleet has a number of hybrid and alternative fuel vehicles, with the goal to add more alternative fuel vehicles as they become available in the market.

As fleet operators with sustainability goals look across their commercial vehicle inventory for greenhouse gas reduction opportunities, they should consider the benefits of both new electric vehicle replacements as well as the repowering of existing vehicles with electric drive systems, especially for those vehicles that have high acquisition cost and a long lifecycle.

"ADOMANI having designed, built and installed zero-emission repower drive systems in a wide range of common commercial fleet vehicles, from the ubiquitous Ford F-150 all the way up to Blue Bird Class-8, school buses, was a primary factor in ADOMANI being considered for this project," said Dennis Brooks, Fleet Manager, County of Santa Clara. "FAF Fleet Management is looking forward to evaluating the repower of the first Sheriff's Blue Bird transport bus and looking at all possible future applications of retrofitting vehicles to EV and of new EV products that we could possibly utilize in the fleet."

"It's not uncommon for certain commercial fleet vehicles to go through a mid-lifecycle repower and receive a new internal combustion engine (ICE) but we'd argue this is really the most opportune time to repower this fleet asset to zero-emission, electric drive and accelerate their overall transition towards a greener fleet," said Jim Reynolds, CEO of ADOMANI. "Beyond meeting increasingly challenging sustainability and compliance guidelines, fleet operators can benefit from a lower cost per mile of operation and maintenance and a cleaner surrounding environment for their drivers, passengers and the communities where they operate. This latest project with Santa Clara County gives us an opportunity to fine tune our vendor supply chain and build economies of scale in the purchase of some key components. With the year-over-year incremental improvements in battery energy density and cost; the improvements in drivetrain component availability and durability; the global trend toward the electrification of transportation; and the incredibly aggressive timeframes imposed by various regulatory agencies, we continue to believe repower projects are an exciting target with an enormous potential market for ADOMANI."

About ADOMANI®

ADOMANI, Inc. is a provider of zero-emission electric drivetrain systems for integration in new school buses and medium to heavy-duty commercial fleet vehicles, as well as re-power conversion kits for the replacement of drivetrain systems in combustion-powered vehicles. ADOMANI is also a provider of new zero-emission electric vehicles focused on reducing the total cost of vehicle ownership, and helps fleet operators unlock the benefits of green technology and address the challenges of traditional fuel price cost instability and local, state and federal environmental regulatory compliance. For more information visit www.ADOMANIelectric.com

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that relate to future plans, events, financial results, prospects or performance are forward-looking statements. While they are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in ADOMANI's reports filed with the Securities and Exchange Commission, all of which are available online at www.sec.gov. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "planned," "expects," "believes," "strategy," "opportunity," "anticipates," "outlook," "designed," and similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, ADOMANI® undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Contact Information

Investor Relations Contacts:

ADOMANI, Inc.

Kevin Kanning, VP Investor Relations
Telephone: (650) 533-7629
Email: kevin.k@ADOMANIelectric.com

Michael K. Menerey, Chief Financial Officer
Telephone: (951) 407-9860 ext. 205
Email: mike.m@ADOMANIelectric.com

Renmark Financial Communications, Inc.

Joshua Lavers: jlavers@renmarkfinancial.com
Telephone: (416) 644-2020, ext. 3409 or (514) 939-3989

SOURCE: ADOMANI, Inc.

ReleaseID: 569339

LOS ANGELES, CA / ACCESSWIRE / December 9, 2019 / Bay Talent Group (TSXV:HIRE), growing global network of boutique executive search, staffing, consulting and technology companies that provide talent acquisition and professional team development solutions. Allan Hartley, CEO of Bay Talent Group will be presenting and meeting with investors at the 12th annual LD Micro Main Event on Wednesday, December 11th at 1:40PM PST / 4:40PM EST.

"This year's Main Event is our largest event to date, with 275 companies set to present and meet with investors" stated Chris Lahiji, President of LD Micro. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever-growing community. Investor interest in our events has also never been stronger, and that goes for our commitment to philanthropy as well."

The LD Micro Main Event will take place on December 10th-12th in Los Angeles, at the Luxe Sunset Bel Air Hotel, which will feature 275 companies, and will be attended by over 1,400 individuals.

Profiles powered by LD Micro – News Compliments of Accesswire

About Bay Talent Group

Bay Talent Group's strategy is to complete accretive acquisitions of staffing, information technology, and consulting firms that meet BTG's valuation, expertise, geographic, and operational criteria. BTG proposes to create value by providing diversified vertical and cross-selling opportunities to target firms, realizing savings from consolidating operations and leveraging a centralized back-office structure. Bay Talent Group's mission is to transform the staffing industry through building a network of companies, focusing on digital innovation, and providing unique profit-sharing partnership programs.

Bay Talent was formed under the laws of the Province of Ontario on June 2, 2017. BTG's two wholly-owned operating subsidiaries, Provision IT Resources Ltd. ("Provision") and PTC Accounting and Finance Inc. ("PTC"), are boutique consulting firms that offer a range of professional staffing services for accounting, finance, information technology, and human resources. Their client base includes large organizations in the financial, government, insurance, and pension fund sectors, as well as, small and medium sized businesses across a broad range of industries.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Allan Hartley
Phone: (617)- 513 -1657
Address: 333 Bay St, Suite 1700 Toronto ON M5H 2R2
Email: ahartley@baytalentgroup.com

SOURCE: Bay Talent Group via LD Micro

ReleaseID: 569313

SHELTON, CT / ACCESSWIRE / December 9, 2019 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in nanomedicines against viruses, held its annual meeting of shareholders of the Company on Saturday, December 7th, 2019 at 10:00 a.m., Eastern Daylight Time. The meeting was held at the Sheraton Stamford Hotel, 700 East Main Street, Stamford Connecticut 06901.

Upon adjournment of the business portion of the meeting, it was opened for questions from shareholders.

In response to questions from shareholders regarding a timeline for the Company's first IND filing with the US FDA, Dr. Diwan reported that the timeline was extremely dependent on external collaborators, and as such, the Company could not provide a projected date for filing of the IND. However, the Company anticipates that the IND package could be ready in the next eight weeks or so, if all goes well, and if we obtain all of the external reports expeditiously. He added that the IND package is then required to be converted into the "eCTD" ("electronic Common Technical Document") format in order to be submitted to the US FDA. He stressed that this timeline projection had a high degree of uncertainty due to dependence on multiple external factors, and that the Company is doing its best to finish the task as soon as possible.

Dr. Diwan emphasized that the Company had tested the drug candidate in a human skin-based model of VZV infection, albeit ex vivo (i.e. using human skin patches cultured in petri dishes, not in human beings), for effectiveness as well as for safety. This testing was performed by Professor Jennifer Moffat at the Upstate Medical Center, SUNY, Syracuse, NY. Professor Moffat is an expert in VZV, shingles, and chickenpox.

Given that the testing in human skin patches was successful, the risk in human clinical trials is expected to be relatively minimal, as compared to drugs that are developed using animal models of disease.

Dr. Diwan also stressed that the Company had gone to great lengths to develop analytical techniques and perform characterization of the manufactured drug in order to de-risk the manufacturing quality and to provide well characterized, cGMP manufactured materials for the anticipated clinical programs. He noted that nanomedicines such as the Company's nanoviricides are complex materials that, as a class, have been challenging to characterize, and that the Company is learning from past failures in this class of drugs. He reported that the Company has therefore spent substantial amount of time in developing analytical techniques and critical quality attributes in order to be able to manufacture consistent quality of drug from batch to batch.

In response to questions regarding financing, Dr. Diwan reported that he had provided a personal debt commitment to the Company for $2 million to bridge over the current cash flow situation and to be able to complete an IND filing. He also reported that the Company had filed for an underwritten common-stock-only secondary public offering on Form S-1 with the SEC on November 27th, 2019, and that the Company is awaiting SEC clearance in order to execute on the sale of common stock under this offering to bolster its cash position.

In response to additional questions requesting more details on NV-HHV-101 development, Dr. Diwan provided further information on the activities that are going on towards the filing of the first IND of the Company, namely, NV-HHV-101 for the topical dermal treatment of shingles rash. He reported that "The in-life animal studies portions of the required GLP safety/toxicology studies were already completed and resulting blood samples were sent by the contract research organization, BASi, Indiana, to other laboratories for different analyses. The Company had also sent the NV-HHV-101 drug product for other required testing to other laboratories. Most of the studies have been completed by the external collaborators and the Company is awaiting draft reports from the completed studies to guide the IND application drafting. Thereafter, the Company will need the final quality-controlled documents of the required safety/toxicology and related studies from these external collaborators for inclusion in the IND package. The Company is already working on the Chemistry, Manufacture, and Controls section of the IND filing. The Company is also in the process of retaining consultants to help develop the clinical protocols to be included in the IND. The Company is also in the process of identifying and contracting with a clinical contract research organization with expertise in VZV shingles studies. Finally, the Company is in the process of retaining a consultant for performing the required conversion of the IND package documents into the standardized eCTD format. This last step of conversion to eCTD format is expected to take at least two weeks, according to the consultant." He concluded that, "With so many external dependencies, the Company cannot predict or provide guidance for a projected date for the IND filing. However, the development is on track and we anticipate filing an IND as soon as we can complete the application development and eCTD conversion."

The Company's first drug candidate, NV-HHV-101, under the HerpeCide™ program is progressing towards human clinical trials satisfactorily. In light of the successful results that have become available so far in the IND-enabling pre-clinical development studies as reported by the Company in its press releases, the Company has been in the process of interviewing Contract Research Organizations (CRO's) that can perform human clinical trials of the NV-HHV-101 skin cream towards approval for the dermal topical treatment of shingles rash, as our first indication.

The Company has previously filed a pre-IND application for NV-HHV-101 for the dermal topical treatment of shingles rash with the US FDA and has received favorable responses on our potential study designs.

About 500,000 to 1 million episodes of herpes zoster (shingles) occur annually in the United States alone. In spite of the new Shingrix™ vaccine, the market size for a therapeutic for shingles is estimated to be in excess of $1 billion dollars. There is currently no approved drug against shingles, PHN, or chickenpox, indicating an unmet medical need.

In a human skin organ culture model of VZV infection, this drug candidate, NV-HHV-101, has been shown to be highly effective against VZV. This work was performed by Professor Jennifer Moffat at the SUNY Upstate Medical University, Syracuse, NY.

Since these efficacy studies were performed using human skin, and additionally were complemented with histological observations regarding safety, the Company believes that this work has laid the foundation towards success in human clinical trials.

The Company is working on developing drugs against several indications in our HerpeCide™ program. The market size for our immediate target drugs in the HerpeCide™ program is variously estimated into billions to tens of billions of dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide™ program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including Oral and Genital Herpes, viral diseases of the eye including EKC and Herpes Keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

FDA refers to US Food and Drug Administration.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
MJ Clyburn
TraDigital IR
clyburn@tradigitalir.com

SOURCE: NanoViricides, Inc.

ReleaseID: 569532